DERMATITIS, ATOPIC

This study tested a new medicine called 611 in 519 Chinese adults with moderate to severe atopic dermatitis (eczema). The drug works by blocking a protein involved in inflammation. The main goal was to see if it could significantly improve skin symptoms like redness and itching a…

This study looked at how dupilumab affects the skin barrier in 44 Chinese patients with moderate to severe atopic dermatitis (eczema). Over 16 weeks, researchers measured water loss from the skin to see if the treatment helped strengthen the barrier. The goal was to understand ho…

This study looked at the long-term safety and effectiveness of a daily pill called abrocitinib for people aged 12 and older with moderate to severe eczema. Over 3,000 participants who had already completed a prior study took either 100 mg or 200 mg of abrocitinib for up to 92 wee…

This study looked at how the medication dupilumab changes the skin barrier in 41 children aged 6 to 12 with moderate to severe eczema. Researchers measured water loss from the skin to see if the treatment helps repair the skin's protective layer. The goal was to understand how du…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe eczema that wasn't helped enough by creams or other treatments. The goal was to see if the drug could clear or nearly clear the skin and reduc…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe eczema that didn't get better with creams. Participants also used standard steroid creams during the trial. The goal was to see if the shot co…

This study tested a new medicine called amlitelimab, given as a shot under the skin, for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that wasn't helped enough by creams or other treatments. About 589 participants received either the study drug or a…

This study looked at how dupilumab, a drug for moderate-to-severe eczema, changes nerve fibers in the skin and reduces itching. 54 adults with chronic itch took part. Researchers took skin samples to measure nerve density and branching before and after treatment.

This study tested a new medication called lunsekimig in 150 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. Participants received one of three doses of the drug or a placebo as a shot under the skin for 24 weeks. Th…

This early-stage study tested a new drug called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema). The main goal was to check the drug's safety and how the body processes it. Participants received a single dose of the drug or a placebo, and researchers mo…

This study tested a new medication called SCD-044 in 250 adults with moderate to severe eczema (atopic dermatitis). The goal was to see if it could improve skin symptoms better than a placebo over 16 weeks. Researchers measured how many people achieved at least 75% improvement in…

This study tested an experimental drug called BI 655130 in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo through an IV, and researchers measured changes in skin redness, thickness, and itching over 16 weeks. The g…

This study looked at how well vaccines work in adults with moderate-to-severe eczema who are taking the drug amlitelimab. 224 participants received either amlitelimab or a placebo, along with tetanus and pneumonia vaccines. The goal was to see if the drug changes the body's immun…

This study looked at how a new medicine called amlitelimab affects the way the body processes other drugs in adults with moderate-to-severe atopic dermatitis (eczema). 23 participants took part. The goal was to understand potential drug interactions to ensure safe use with other …